Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy [1]

Journal of the American Academy of Dermatology

Volumn 50, Issue 3, 2004, Pages 475-476

  Huber, Margit A ^a,b   Kunzi Rapp, Karin ^b   Staib, Gyde ^b   Scharffetter Kochanek, Karin ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEXAROTENE; LEVOTHYROXINE;

AGED; CASE REPORT; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTHYROIDISM; LETTER; MALE; MYCOSIS FUNGOIDES; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; TREATMENT OUTCOME;

EID: 1542374013     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)02488-5     Document Type: Article

References (5)

1. Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000;1:245-50.
2. Duvic M, Martin AG, Kim Y, Olsen E, Wood G, Crowley CA, et al. Phase II and III clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
3. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
4. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase I and II trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32.
5. Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology 1999;199:102-5.